TriHealth Advances Lung Cancer Diagnosis and Treatment Through New AI Partnership
TriHealth, a nationally recognized healthcare system based in Cincinnati, Ohio, has announced a new partnership with RevealDx, a company specializing in Medical Imaging Artificial Intelligence, to bring greater precision and personalization to the diagnosis and management of lung nodules.
Lung nodules are relatively common findings on imaging, but while most are benign, a small percentage can represent early-stage lung cancer. Timely and accurate assessment is critical. TriHealth has already established itself as a leader in this area by implementing robotic bronchoscopy, an advanced technique that enables faster, more accurate tissue sampling with shorter recovery times for patients.
To further improve outcomes, TriHealth has recently integrated:
- Riverain Technologies’ software to enhance nodule detection on CT scans
- Thynk Health’s software to streamline the identification and management of lung nodules while providing outcome analytics
The new collaboration with RevealDx will launch with a clinical study aimed at evaluating the real-world impact of AI on identifying lung nodules at higher risk for cancer. In addition to clinical outcomes, the study will measure the financial and operational impact of using this integrated program in settings with high chest CT volumes and active lung cancer screening programs.
“For decades, lung nodule assessment has followed a pattern of detection, measurement, and repeated scanning—often resulting in delayed diagnosis of lung cancer,” said Dr. Doug Adams of TriHealth. “AI tools now offer the potential to deliver critical insights at the very first scan. When paired with AI-driven informatics, this represents a significant step forward. We’re eager to study how these tools improve care in a real-world setting.”
The clinical study will involve contributions from RevealDx, Thynk Health, and Riverain Technologies, with funding support provided by RevealDx.